[HTML][HTML] CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER …
Introduction We studied whether fully automated Elecsys cerebrospinal fluid (CSF)
immunoassay results were concordant with positron emission tomography (PET) and
predicted clinical progression, even with cutoffs established in an independent cohort.
Methods Cutoffs for Elecsys amyloid-β 1–42 (Aβ), total tau/Aβ (1–42), and phosphorylated
tau/Aβ (1–42) were defined against [18 F] flutemetamol PET in Swedish BioFINDER (n=
277) and validated against [18 F] florbetapir PET in Alzheimer's Disease Neuroimaging …
immunoassay results were concordant with positron emission tomography (PET) and
predicted clinical progression, even with cutoffs established in an independent cohort.
Methods Cutoffs for Elecsys amyloid-β 1–42 (Aβ), total tau/Aβ (1–42), and phosphorylated
tau/Aβ (1–42) were defined against [18 F] flutemetamol PET in Swedish BioFINDER (n=
277) and validated against [18 F] florbetapir PET in Alzheimer's Disease Neuroimaging …
以上显示的是最相近的搜索结果。 查看全部搜索结果